1-20 of 39
S Hurvitz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract ES1-3: The ideal partner to HER2 directed therapies

S Hurvitz
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): ES1-3.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-ES1-3
Published: 15 February 2022
View article
Journal Articles

Abstract OT2-07-08: Withdrawn

E Paplomata, V Borges, S Loi, V Abramson, E Hamilton, S Hurvitz, N Lin, L Walker, RK Murthy
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): OT2-07-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-OT2-07-08
Published: 15 February 2019
View article
Journal Articles

Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer

DA Yardley, M Abu-Khalaf, V Boni, A Brufsky, LA Emens, M Gutierrez, S Hurvitz, S-A Im, S Loi, SL McCune, P Schmid, C O'Hear, X Zhang, GA Vidal
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): OT2-06-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-OT2-06-04
Published: 15 February 2019
View article
Journal Articles

Abstract P2-13-03: The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials

S Delaloge, S Hurvitz, N Chan, R Bose, RC Jankowitz, M Thirlwell, I Láng, A ten Tije, M Trudeau, CR Osborne, Z-Z Shen, D Lalla, F Xu, D Hunt, E Olek, D Tripathy, HS Rugo, J Chien, A Chan, CH Barcenas
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P2-13-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P2-13-03
Published: 15 February 2019
View article
Journal Articles

Abstract P3-10-08: Markers of response to CDK4 & 6 inhibition from neoMONARCH: A phase II neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive, HER2 negative breast cancer

S Hurvitz, M Martin, S Wijayawardana, M Brahmachary, PJ Ebert, S Young, V Jansen, D Slamon
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P3-10-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P3-10-08
Published: 15 February 2019
View article
Journal Articles

Abstract PD2-10: Treatment with abemaciclib modulates the immune response in gene expression analysis of the neoMONARCH neoadjuvant study of abemaciclib in postmenopausal women with HR+, HER2 negative breast cancer

S Hurvitz, M Martin, M Press, S Wijayawardana, M Brahmachary, PJ Ebert, S Young, V Jansen, D Slamon
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): PD2-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-PD2-10
Published: 15 February 2019
View article
Journal Articles

Abstract P6-18-05: First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis

D Tripathy, G Hortobagyi, A Chan, S-A Im, S Chia, D Yardley, FJ Esteva, S Hurvitz, O Kong, W Bao, K Rodriguez Lorenc, I Diaz-Padilla, DJ Slamon
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-18-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-18-05
Published: 15 February 2019
View article
Journal Articles

Abstract P6-18-04: Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis

D Tripathy, S Campos-Gomez, Y-S Lu, F Franke, A Bardia, P Wheatley-Price, FM Cruz, R Hegg, F Cardoso, A Gaur, O Kong, I Diaz-Padilla, M Miller, S Hurvitz
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-18-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-18-04
Published: 15 February 2019
View article
Journal Articles

Abstract P6-17-36: Consensus and disagreement among experts for treatment of patients with HER2+ early-stage breast cancer suggests unmet need for online decision support tool

FA Holmes, KM Rosenthal, S Hurvitz, MD Pegram, DA Yardley, KL Obholz, J O'Shaughnessy
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-17-36.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-17-36
Published: 15 February 2019
View article
Journal Articles

Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials

JT Beck, P Neven, FJ Esteva, A Bardia, N Harbeck, S Hurvitz, J O'Shaughnessy, S Verma, B Lanoue, J Alam, O Kong, D Chandiwana, S Chia
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-18-14.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-18-14
Published: 15 February 2019
View article
Journal Articles

Abstract P6-17-11: The small molecule inhibitor of HER2, tucatinib, has potent and highly selective activity in preclinical modes of HER2-driven cancer

NA O'Brien, D Conklin, M McDermott, T Luo, R Ayala, S Issakhanian, S Salgar, S Hurvitz, DJ Slamon
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-17-11.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-17-11
Published: 15 February 2019
View article
Journal Articles

Abstract P1-06-10: Correlative analysis of breast cancer index (BCI) restratification of 21-gene recurrence score (RS) in patients with hormone receptor-positive (HR+), node-negative breast cancer

F Yan, AK Master, MA Israel, J Liu, CA Schnabel, S Hurvitz, VK Gadi
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P1-06-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P1-06-10
Published: 15 February 2018
View article
Journal Articles

Abstract P3-14-01: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: The CONTROL trial

S Hurvitz, A Chan, N Iannotti, E Ibrahim, J Chien, N Chan, A Kellum, V Hansen, G Marx, SD Kendall, M Wilkinson, A Castrellon, R Ruiz, P Fang, D Hunt, S Moran, E Olek, CH Barcenas, HS Rugo
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P3-14-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P3-14-01
Published: 15 February 2018
View article
Journal Articles

Abstract P4-09-01: A multi-study correlative analysis of change in Ki67 in the neoadjuvant setting and disease free survival improvement in the adjuvant setting

SRD Johnston, MJ Frenzel, ZM Thomas, T Hu, S Barriga, IC Smith, S Hurvitz
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P4-09-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P4-09-01
Published: 15 February 2018
View article
Journal Articles

Abstract PD5-12: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study

M Campone, S-A Im, H Iwata, M Clemons, Y Ito, A Awada, S Chia, A Jagiełło-Gruszfeld, B Pistilli, L-M Tseng, S Hurvitz, N Masuda, J Cortés, M De Laurentiis, CL Arteaga, Z Jiang, W Jonat, D Sellami, M El-Hashimy, S Le Mouhaër, B Sankaran, L Bourdeau, J Baselga
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): PD5-12.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD5-12
Published: 15 February 2018
View article
Journal Articles

Abstract PD5-11: Not presented

A Bardia, DA Yardley, S Hurvitz, G Wright, R Moroose, C Ma, L Hart, E Tan-Chiu, S Blau, T Sanft, R Dichmann, A Zelnak, A DeMichele, A Clark, T Small, C Tucci, TS Samant, D Purkayastha, M Karuturi, S Moulder
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): PD5-11.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD5-11
Published: 15 February 2018
View article
Journal Articles

Abstract P5-16-02: Variance between experts and community practitioners in treatment of metastatic breast cancer

TA Quill, KL Blackwell, S Hurvitz, KD Miller, N Robert, KL Obholz, M Jahanzeb
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-16-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-16-02
Published: 15 February 2018
View article
Journal Articles

Abstract P5-16-01: Documenting and sharing breast cancer knowledge from National Cancer Institute designated comprehensive cancer centers (NCI-CCCs) with community oncologists

M Kalra, M Karuturi, D Tripathy, R Jankowitz, K McCann, A Brufsky, S Hurvitz, O Bogler, S Housri, N Housri
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-16-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-16-01
Published: 15 February 2018
View article
Journal Articles

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

J Litton, HS Rugo, J Ettl, S Hurvitz, A Gonçalves, K-H Lee, L Fehrenbacher, R Yerushalmi, LA Mina, M Martin, H Roché, Y-H Im, RGW Quek, IC Tudor, AL Hannah, W Eiermann, JL Blum
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): GS6-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-GS6-07
Published: 15 February 2018
View article
Journal Articles

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

D Tripathy, J Sohn, S-A Im, M Colleoni, F Franke, A Bardia, N Harbeck, S Hurvitz, L Chow, KS Lee, S Campos-Gomez, R Villanueva Vazquez, KH Jung, G Carlson, G Hughes, I Diaz-Padilla, C Germa, S Hirawat, Y-S Lu
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): GS2-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-GS2-05
Published: 15 February 2018
View article